PDCD1 and prostate carcinoma: For example, autologous transplantation of PD-1 knockout T cells are now being studied in several clinical trials (e.g. NCT02793856 for metastatic non-small cell lung cancer and NCT02867345 for castration resistant prostate cancer)26, as an alternative checkpoint blockade strategy to the costly antibody treatment.